Ferrer Internacional S.a.

This study is testing whether an oral medication called FNP-223 can slow the progression of progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and balance. About 241 participants with early-stage PSP will take either the medication or a placebo for …